Total raised
$129 M
2 rounds on record
Latest round
$114 M
Nov 2017
First round on record
Mar 2015
Today
Acquired
Acquired by Vertex Pharmaceuticals Incorporated
Acquired Matched to this startup by its exact name; the buyer's report is the source.
Funding rounds 2 counted as startup funding. Open the number of investors for the round's details.
Funding rounds of Semma Therapeutics, Inc. Month Raised Raise Size Investors Sold Filing Nov 2017 $114 M No. 2 $50 to $250 million 20
Semma Therapeutics, Inc.: Raise no. 2, Nov 2017 × Investors in this round 20 investors had bought by the notice of Feb 26, 2019: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $114 M of $120 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bastiano Sanna · Executive Officer, Director Kingsley Taft · Executive Officer Todd Foley · Executive Officer, Director Daniel Auerbach · Director Kevin Raidy · Director Mark Fishman · Director Mitchell Finer · Director Stephen Knight · Director William Sahlman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Series B Preferred Stock. Total amount sold includes $13,860,712 from note conversions.”Signed by Bastiano Sanna, Chief Executive Officer. Newest notice filed Feb 26, 2019 (1 amendment). Read the notice at the SEC .
equity SEC Mar 2015 $15 M No. 1 $10 to $50 million 10
Semma Therapeutics, Inc.: Raise no. 1, Mar 2015 × Investors in this round 10 investors had bought by the notice of Mar 31, 2016: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $25 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kingsley Taft · Executive Officer Robert Millman · Executive Officer, Director Todd Foley · Executive Officer, Director Jim Scopa · Director Mitch Finer · Director Stephen Knight · Director William Sahlman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Series A Preferred Stock”Signed by Robert Millman, President. Newest notice filed Mar 31, 2016 (1 amendment). Read the notice at the SEC .
equity SEC
What its filings and its own website say, sentence by sentence, each with its source.
Semma Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2019).
SEC Form D · Feb 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2019
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
No investor of Semma Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Semma Therapeutics, Inc. Name Role Named in Bastiano Sanna Executive officer Feb 2019 Kingsley Taft Executive officer Feb 2019 Todd Foley Executive officer Feb 2019 Elizabeth Stoner Executive officer Dec 2017 Robert Millman Executive officer Mar 2016 Bastiano Sanna Director Feb 2019 Daniel Auerbach Director Feb 2019 Kevin Raidy Director Feb 2019 Mark Fishman Director Feb 2019 Mitchell Finer Director Feb 2019 Stephen Knight Director Feb 2019 Todd Foley Director Feb 2019 William Sahlman Director Feb 2019 Jim Scopa Director Mar 2016 Mitch Finer Director Mar 2016 Robert Millman Director Mar 2016
Acquired (Jan 1, 2019). Acquired by Vertex Pharmaceuticals Incorporated.